Simplify Asset Management Inc. Sells 19,885 Shares of Establishment Labs Holdings Inc. $ESTA

Simplify Asset Management Inc. decreased its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 27.3% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 53,009 shares of the company’s stock after selling 19,885 shares during the period. Simplify Asset Management Inc.’s holdings in Establishment Labs were worth $3,010,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Establishment Labs by 20.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock valued at $2,335,000 after acquiring an additional 9,557 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Establishment Labs by 1.2% during the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after acquiring an additional 299 shares during the last quarter. WINTON GROUP Ltd bought a new stake in Establishment Labs during the second quarter worth $651,000. Nebula Research & Development LLC lifted its holdings in Establishment Labs by 27.9% during the second quarter. Nebula Research & Development LLC now owns 16,214 shares of the company’s stock worth $692,000 after acquiring an additional 3,538 shares during the period. Finally, Sei Investments Co. boosted its position in Establishment Labs by 13.3% in the second quarter. Sei Investments Co. now owns 48,428 shares of the company’s stock worth $2,068,000 after purchasing an additional 5,668 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ESTA shares. TD Cowen restated a “buy” rating on shares of Establishment Labs in a research note on Monday, June 8th. Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a research note on Wednesday, May 6th. Wall Street Zen downgraded shares of Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. BTIG Research lifted their price objective on shares of Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $87.14.

Insider Activity

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the sale, the director directly owned 927,504 shares in the company, valued at approximately $69,952,351.68. This represents a 10.17% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 292,500 shares of company stock valued at $20,591,021 over the last 90 days. Insiders own 9.99% of the company’s stock.

Establishment Labs Stock Performance

Shares of ESTA opened at $89.25 on Friday. Establishment Labs Holdings Inc. has a fifty-two week low of $33.35 and a fifty-two week high of $90.50. The business has a 50-day moving average of $75.84 and a 200 day moving average of $70.92. The firm has a market cap of $2.63 billion, a P/E ratio of -59.90 and a beta of 1.06. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The business had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. Establishment Labs’s revenue for the quarter was up 44.7% compared to the same quarter last year. During the same period last year, the company earned ($0.70) earnings per share. As a group, research analysts forecast that Establishment Labs Holdings Inc. will post -1.07 EPS for the current year.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.